Bryan Garnier - Transfer of coverage

Report

Bryan Garnier

Healthcare Team

Transfer of coverage

From 3rd March 2025, coverage of Abivax, Valneva and Basilea will be transferred to Oscar Haffen-Lamm.Coverage of DBV Technologies, EVOTEC, GENFIT, INNATE Pharma, INVENTIVA and MEDIOS will be transferred to the Healthcare Team.

03/03/2025 1 EN

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Healthcare Team

Other Reports from Bryan Garnier

Oscar Haffen Lamm

Oscar Haffen Lamm

Valneva: CHMP positive opinion on Ixchiq's label extension in adolescents

Friday Valneva announced the positive opinion of the CHMP regarding the label extension of Ixchiq to adolescents (aged 12-18 y.o). The next step will be for the EC to review the CHMP recommendation, with a decision on approval within 60 days. As a reminder, the decision is supported by 6-months ado

23h / 23m 23h / 23m 1 EN

Clement Genelot

Clement Genelot

Casino: covenants still look unsustainable from late 2026

Post-FY 2024, we have cut our FY 2025-27e sales / EBITDA / FCF by 2% / 12% / >6% respectively to reflect a softer-than-expected 2024 landing. Our updated estimates still point to net debt and a gross cash covenants breach from late 2026 with the same old concern around the stock: the dilution ri

23h / 58m 23h / 58m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Transfer of coverage

Valneva: CHMP positive opinion on Ixchiq's label extension in adolescents

Casino: covenants still look unsustainable from late 2026

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe